Verona Pharma

Research & Development

We aim to improve health and quality of life for the millions of people affected by chronic respiratory diseases. Our first-in-class development candidate, ensifentrine (RPL554), has the potential to provide relief for patients suffering from respiratory conditions such as chronic obstructive pulmonary disease (COPD), COVID-19, cystic fibrosis (CF) and asthma.